September 3, 2021

BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East)
Mumbai 400 051

Scrip Code: 500325 / 890147
Trading Symbol: RELIANCE/ RELIANCEP1

Dear Sirs,

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Investment in Strand Life Sciences Private Limited

Reliance Strategic Business Ventures Limited (“RSBVL”), a wholly owned subsidiary of Reliance Industries Limited (“RIL” or the “Company”) has acquired 2,28,42,654 equity shares of Rs.10 each of Strand Life Sciences Private Limited (“Strand”) for a cash consideration of Rs 393 crores only (Indian Rupees Three Hundred Ninety three crores only).

A further investment of up to Rs 160 crore (Indian Rupees One Hundred Sixty Crore only) is expected to be completed by March, 2023. The total investment will translate into ~80.3% of equity share capital in Strand on a fully diluted basis.

Strand was incorporated in India on October 6, 2000. Strand is a pioneer of genomic testing in India with bioinformatics software and clinical research solutions to healthcare providers including clinicians, hospitals, medical devices manufacturers and pharmaceutical companies.

Strand’s turnover was Rs 88.70 crore, Rs 109.84 crore and Rs 96.60 crore, and Net Profit (Loss) of Rs 8.48 crore, Rs (25.04) crore and Rs (21.66) crore in FY 2021, FY 2020 and FY 2019 respectively.

The aforesaid investment is part of group’s digital health initiatives, to foster affordable access to world class technology and innovation led healthcare ecosystem in India.

No governmental or regulatory approvals were required for the said investment. The investment does not fall within related party transactions and none of RIL’s promoter / promoter group / group companies have any interest in the transaction.

Thanking you,

Yours faithfully,

For Reliance Industries Limited

Savitri Parekh
Joint Company Secretary and Compliance Officer

Copy to:
The Luxembourg Stock Exchange
35A boulevard Joseph II
L-1840 Luxembourg

Singapore Stock Exchange
2 Shenton Way, #19-00 SGX Centre
1, Singapore 068804

Regd. Office: 3rd Floor, Maker Chambers IV, 222, Nariman Point, Mumbai- 400 021, India
Phone #: +91-22-3555 5000, Telefax: +91-22-2204 2268. E-mail: investor.relations@ril.com, Website: www.ril.com
CIN- L17110MH1973PLC019786